Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies

A method of treating or preventing HIV in a human subject in need thereof, the method comprising:

• a) Identifying a human subject who is infected with an HIV or a population of HIV expressing a gp120 comprising the following amino acid residues:
• N332glycan, D325, and one or more amino acid residues selected from the group consisting of T63, L179, T320, and H330, wherein the amino acid positions are with reference to SEQ ID NO:
• 4;
• and
• b) Administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that competes with or comprises VH and VL regions that bind to an epitope of gp120 within the third variable loop (V3) and/or high mannose patch comprising a N332 oligomannose glycan;
• and
• c) Administering to the subject a second antibody or antigen binding fragment thereof that binds to an epitope or region of gp120 selected from the group consisting of:
• i. second variable loop (V2) and/or Env trimer apex;
• ii. CD4 binding site (CD4bs);
• iii. gp120/gp41 interface;
• or
• iv. silent face of gp120.